Outrageous prices of orphan drugs: a call for collaboration

The Lancet

Volumn 392, Issue 10149, 2018, Pages 791-794

  Luzzatto, Lucio ^a   Hyry, Hanna I ^b   Schieppati, Arrigo ^c   Costa, Enrico ^d   Simoens, Steven ^e   Schaefer, Franz ^f   Roos, Jonathan C P ^b   Merlini, Giampaolo ^g   Kääriäinen, Helena ^h   Garattini, Silvio ⁱ   Hollak, Carla E M ^j   Remuzzi, Giuseppe ^i,k,l   Barbui, Tiziano ^m   Benigni, Ariela ^m   Daina, Erica ^m   Gramaglia, Donatella ^m   Kaarinen, Helena ^m   Licht, Christoph ^m   Notaro, Rosario ^m  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Rare Diseases Unit AO Papa Giovanni XXIII   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF PAVIA   (Italy)

^h NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

ⁱ MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE POLICY; HUMAN; NOTE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SUSTAINABLE DEVELOPMENT; DRUG DEVELOPMENT; DRUG MANUFACTURE; ECONOMICS; EUROPEAN UNION; INTERPERSONAL COMMUNICATION; LEGISLATION AND JURISPRUDENCE; RARE DISEASE;

COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG DISCOVERY; EUROPEAN UNION; HUMANS; NEGOTIATING; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 85054890706     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31069-9     Document Type: Note

References (30)

1. US Food and Drug Administration. Orphan Drug Act, Pub L. No. 97-414, 96 Stat. 2049. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm364750.htm. (Accessed 1 March 2018)
2. Office of Orphan Products Development. List of orphan designations and approvals. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm. (Accessed 1 March 2018)
3. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (consolidated version.7/8/2009). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF. (Accessed 1 March 2018)
4. Harper, M, The world most expensive drugs. https://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html#2fb30c285e10, Feb 22, 2010 (March 1, 2018).
5. America's Health Insurance Plans. Orphan Drug Utilization and Pricing pattern (2012–2014). https://www.ahip.org/wpcontent/uploads/2016/10/OrphanDrug_DataBrief_10.21.16.pdf. (Accessed 1 March 2018)
6. Henrard, S, Arickx, F, Negotiating prices of drugs for rare diseases. Bull World Health Organ 94 (2016), 779–781.
7. Hughes-Wilson, W, Palma, A, Schuurman, A, Simoens, S, Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?. Orphanet J Rare Dis, 7, 2012, 74.
8. Luzzatto, L, Hollak, CE, Cox, TM, et al. Rare diseases and effective treatments: are we delivering?. Lancet 385 (2015), 750–752.
9. Orphanet. About rare diseases. http://www.orpha.net/consor/cgi-bin/Education_AboutRareDiseases.php?lng=EN. (Accessed 1 March 2018)
10. Rare list. Global genes. https://globalgenes.org/rarelist/. (Accessed 1 March 2018)
11. Boyd, N, Dancey, JE, Gilks, CB, Huntsman, DG, Rare cancers: a sea of opportunity. Lancet Oncol 17 (2016), e52–e61.
12. Gatta, G, Capocaccia, R, Trama, A, Martínez-García, C, RARECARE Working Group. The burden of rare cancers in Europe. Adv Exp Med Biol 686 (2010), 285–303.
13. Cooper, WA, O'Toole, S, Boyer, M, Horvath, L, Mahar, A, What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology 43 (2011), 103–115.
14. European Medicines Agency. Orphan Medicine figures. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/04/WC500185766.pdf. (Accessed 1 March 2018)
15. Van Rossum, A, Holsopple, M, Enzyme replacement or substrate reduction? A review of Gaucher disease treatment options. Hosp Pharm 51 (2016), 553–563.
16. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. https://www.nice.org.uk/process/pmg9/chapter/foreword, 2013. (Accessed 1 March 2018)
17. Hyry, HI, Stern, AD, Cox, TM, Roos, JC, Limits on use of health economic assessments for rare diseases. QJM 107 (2014), 241–245.
18. European Medicine Agency. Final report on adaptive pathways pilot. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/08/WC500211526.pdf. (Accessed 1 March 2018)
19. Wyden, R, Grassley, CE, United States Senate Committee on finance. http://www.finance.senate.gov/imo/media/doc/Wyden-Grassley%20Document%20Request%20to%20Gilead%207-11-141.pdf, July 11, 2014. (Accessed 1 March 2018)
20. Sarpatwari, A, Avorn, J, Kesselheim, AS, State initiatives to control medication costs—can transparency legislation help?. N Engl J Med 374 (2016), 2301–2304.
21. Avorn, J, The $2·6 billion pill—methodologic and policy considerations. N Engl J Med 372 (2015), 1877–1879.
22. Platt, OS, Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358 (2008), 1362–1369.
23. Orphan designation. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000424.jsp&mid=WC0b01ac058001d12b. (Accessed 1 March 2018)
24. Rowe, SM, Borowitz, DS, Burns, JL, et al. Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax 67 (2012), 882–890.
25. Boseley, S, Health secretary urged to tear up patent on breast cancer drug. The Guardian, Oct 25, 2015.
26. Committee on Petitions. Opinion of the Committee on Petitions for the Committee on the Environment. Public Health and Food Safety on the EU options for improving access to medicines. (2016/2057(INI)). http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&reference=PE-582.217&format=PDF&language=EN&secondRef=02. (Accessed 1 March 2018)
27. Kole, A, Faurisson, F, Rare diseases social epidemiology: analysis of inequalities. Adv Exp Med Biol 686 (2010), 223–250.
28. Stiglitz, JE, The price of inequality: how today's divided society endangers our future. 2013, Norton & co, New York, NY.
29. Bartunek, R-J, Belgium, Netherlands plan joint purchase of rare disease drugs. http://www.reuters.com/article/us-belgium-netherlands-healthcare-idUSKBN0NC11Z20150421. (Accessed 1 March 2018)
30. Communiqué de presse. 24 Septembre 2015. The Grand Duchy of Luxemburg joins Belgium-Netherlands Initiative on Orphan Drugs. http://www.deblock.belgium.be/fr/grand-duchy-luxemburg-joins-belgium-netherlands-initiative-orphan-drugs. (Accessed 1 March 2018)